Other Populations

This research brief highlights the impact findings from the evaluation of three replications of the Safer Sex Intervention (SSI), a clinic-based intervention intended to reduce the incidence of sexually transmitted infections (STIs) and increase condom use among high-risk sexually active female adolescents.

This research report highlights findings from the evaluation of ¡Cuídate!, an HIV/AIDS prevention program that uses an approach culturally tailored to Latino youth. The study examined data from three different replications of ¡Cuídate!, pooling the data to examine the overall program impact.

This research report details findings from the evaluation of Reducing the Risk, a sexual health curriculum developed in the early 1990s to help prevent pregnancy and reduce sexually-transmitted infections (STIs) in adolescents. The study examined data from three different replications of Reducing the Risk, pooling the data to examine the overall program impact.

This research brief highlights findings from the evaluation of ¡Cuídate!, an HIV/AIDS prevention program that uses an approach culturally tailored to Latino youth. The study examined data from three different replications of ¡Cuídate!, pooling the data to examine the overall program impact.

This research report details the impact findings from the evaluation of three replications of the Safer Sex Intervention (SSI), a clinic-based intervention intended to reduce the incidence of sexually transmitted infections (STIs) and increase condom use among high-risk sexually active female adolescents.

This research brief highlights findings from the evaluation of Reducing the Risk, a sexual health curriculum developed in the early 1990s to help prevent pregnancy and reduce sexually-transmitted infections (STIs) in adolescents. The study examined data from three different replications of Reducing the Risk, pooling the data to examine the overall program impact.

The prices charged by drug manufacturers to wholesalers and distributors (commonly referred to as exmanufacturers prices) in the United States are 1.8 times higher than in other countries for the top drugs by total expenditures separately paid under Medicare Part B. U.S. prices were higher for most of the drugs included in the analysis, and U.S.

This is the PDF version of the 2018 Update of the National Plan to Address Alzheimer's Disease. More information about the National Alzheimer's Project Act is available at https://aspe.hhs.gov/national-alzheimers-project-act.

Medicare Advantage (MA) plans that serve relatively higher proportions of dually enrolled beneficiaries have lower ratings in the MA Star Rating program than plans that serve fewer dually enrolled beneficiaries. However, some MA plans that serve a high proportion of dually enrolled beneficiaries are high performers.

The Centers for Medicare and Medicaid Services (CMS) uses the Star Rating program to measure the quality of Medicare Advantage (MA) plans, publicly report plan performance, and determine quality bonus payments and rebates for MA plans.